



GlaxoSmithKline Pharmaceuticals Ltd.
GSK House,
Dr. Annie Besant Road, Worli,
Mumbai - 400 030

Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

7th February 2019

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir / Madam,

Subject: Un-Audited Financial Results Publication for December quarter

Pursuant to Clause 30 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating to publication of Un-Audited Financial Results for quarter ended 31st December 2018.

Thanking you,

 Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited



Ajay Nadkarni
Vice President – Admin, Real Estate
& Company Secretary

Encl: Public Notice

The Quarter and		
(₹ in Lakhs)		
Year to Date - Unaudited		Year Ended - Audited
31.12.2018	31.12.2017	31.03.2018
7106.33	7311.11	9015.93
(801.74)	(311.37)	(717.56)
(801.74)	(311.37)	(717.56)
(527.75)	(185.27)	(470.36)
(526.44)	(187.66)	(468.61)
750.86	750.86	750.86
(1.41)	(0.49)	(1.25)
(1.41)	(0.49)	(1.25)

Act, 2013, read with the relevant rules issued
 Regulation 33 of the SEBI (Listing Obligations and
 Disclosure Requirements) Regulations, 2015 and
 Stock Exchange website www.bseindia.com and
 respective meetings held on February 04, 2019.
 For and on behalf of the Board
Modern India Limited
 Sd/-
Vijay Kumar Jatia
 Chairman & Managing Director
 DIN - 00096977

The undersigned being the Officer of NKGSB Co-op. Bank Ltd. under the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest (Enforcement) Act, 2002 (SARFAESI) and in exercise of powers conferred under Section 13(12) read with Rule 3 of the Security Interest (Enforcement) Rules, 2002 issued demand notice on 11.09.2018 calling upon the following borrowers to repay the amount mentioned in the notice within 60 days from the date of the receipt of said notice.

The borrower having failed to repay the amount, notice is hereby given to the Borrower and the public in general that the undersigned has taken Symbolic Possession of the Assets described here in below in exercise of the powers conferred on him under section 13 (4) of the said Act read with Rule 8 of the said Rules on below mentioned dates u/sec. 14 of the SARFAESI Act.

The borrower, mortgagor and guarantors in particular and public in general are hereby cautioned not to deal with the below mentioned properties and any dealing with the said Assets will be subject to the charge of the NKGSB Co-op. Bank Ltd. for the following amount and interest thereon from 31.12.2018.

The borrower's attention is invited to provisions of sub-section (8) of section 13 of the Act, in respect of time available, to redeem the secured assets.

Name of the Borrower / Partners / Guarantors	Description of the Assets Charged	Date of Symbolic Possession	Amt o/s as on 31.12.2018 (Rs. in lacs)
1) M/s. Modern Petro Packagings Ltd 2. Mr. Karsan Umed Kapadi 3. Mr. Dilip Karsan Patel 4. Mrs. Meena Karsan Patel 5. Mr. Uday Ratilal Charania	All that piece and parcel of Land Bearing Survey No. 53/3-B admeasuring 996 sq.mts together with the building known as "Venus Estate" (comprising of galas admeasuring (i) 1800sq.ft Built up area on the first floor (ii) 2797.60 sq.ft Built up area on the first floor and (iii) 1681.50sq.ft built up area on the second Floor. Situate lying being bearing Panchayat House No.85/U at village Ringarwada, Nani Daman, Taluka and Dist Daman, owned by M/s. Modern Petro Packaging Ltd.	30.01.2019	211.88

Hypothecation of Machineries lying in the factory premises

Sr. No.	Name of Machines	Nos
1	60" ABA Blow Fim Plant 60mm Single Screw Extruder with motor and gear 55mm Single Screw Extruder with motor and gear L/D ratio 28:1 of Both Screw Bubble Basket with adjustable diameter Films die set of 100mm and 250mm 20 HP AC electric motor and AC Frequency Drive Helical Gear Box Rotating Die with rotating air ring corona treatment Plant Slitting and trimming system Hopper Loader	1
2	45" Monolayer Blow Fim Plant 45mm Single Screw L/D ratio 28:1 Bubble Basket with adjustable diameter Films die set of 100mm and 250mm 15 HP AC electric motor and AC Frequency Drive Helical Gear Box Rottating Die with rotating air ring corona treatment Plant Sleatting and trimming system Hopper Loader	1
3	28" Agio Machine with 40HP/1500 RPM Motor	1
4	Flexographic Printing Press 800MM- Two Color (Combi)(Roll to Roll)	1
5	32" Side Sealing Machine	1

Place : Mumbai
 Date : 04.02.2019

Sd/-
AUTHORISED OFFICER,
NKGSB Co-op. Bank Ltd.



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com
 Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2018

(₹ in Lakhs)

	Standalone			
	Unaudited 3 months ended 31.12.18	Unaudited 9 months ended 31.12.18	Unaudited Preceding 3 months ended 30.09.18	Unaudited Corresponding 3 months ended 31.12.17
Total Income from Operations	82535	237731	81631	70391
Profit before Exceptional Items	14165	45649	16825	14038
Profit before tax	16978	46455	15646	14038
Net Profit	11297	30233	10077	8969
Total comprehensive income for the period	10755	29691	10077	9335
Paid-up Equity Share Capital (Face value per share ₹ 10)	16940	16940	16940	8470
Other Equity as shown in the Audited Balance Sheet for the year ended March 31, 2018	199525	199525	199525	199525
Earnings Per Share (EPS) (of ₹ 10 each) (not annualised)				
Basic and diluted EPS (₹)	6.67	17.85	5.95	5.29

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter ended 31st December 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 4th February 2019.

By Order of the Board
Annaswamy Vaidheesh
 Managing Director
 DIN: 1444303

4th February, 2019

Business Standard (Mumbai) 05-02-2019 p.5



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com
Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2018

(₹ in Lakhs)

	Standalone			
	Unaudited 3 months ended 31.12.18	Unaudited 9 months ended 31.12.18	Unaudited Preceding 3 months ended 30.09.18	Unaudited Corresponding 3 months ended 31.12.17
Total Income from Operations	82535	237731	81631	70391
Profit before Exceptional Items	14165	45649	16825	14038
Profit before tax	16978	46455	15646	14038
Net Profit	11297	30233	10077	8969
Total comprehensive income for the period	10755	29691	10077	9335
Paid-up Equity Share Capital (Face value per share ₹ 10)	16940	16940	16940	8470
Other Equity as shown in the Audited Balance Sheet for the year ended March 31, 2018	199525	199525	199525	199525
Earnings Per Share (EPS) (of ₹ 10 each) (not annualised)				
Basic and diluted EPS (₹)	6.67	17.85	5.95	5.29

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter ended 31st December 2018 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 4th February 2019.

By Order of the Board
Annaswamy Vaidheesh
Managing Director
DIN: 1444303

4th February, 2019

Economic Times (Mumbai) 05-02-2019 P-4



ग्लॅक्सोरिस्मथक्लाइन फार्मास्युटिकल्स लिमिटेड

नोंदणीकृत कार्यालय : डॉ. अंनी बेझंट रोड, मुंबई ४०००३० • वेबसाईट : www.gsk-india.com

ई मेल : askus@gsk.com • कॉर्पोरेट आयडेंटिटी क्रमांक : L24239MH1924PLC001151

३१ डिसेंबर, २०१८ ला संपलेल्या तिमाहीकरिता

एकल (Standalone) अलेखापरिक्षित वित्तीय निष्कर्षांचे विवरण

(₹ लाखांत)

	एकल (Standalone)			
	अलेखापरिक्षित ३१.१२.१८ ला संपलेले ३ महिने	अलेखापरिक्षित ३१.१२.१८ ला संपलेले ९ महिने	अलेखापरिक्षित ३०.०९.१८ ला संपलेले पूर्ववर्ती ३ महिने	अलेखापरिक्षित ३१.१२.१७ ला संपलेले अनुरूप ३ महिने
प्रचलनातून एकूण उत्पन्न	८२५३५	२३७७३१	८१६३१	७०३९१
अपवादात्मक बाबींपूर्वी नफा	१४१६५	४५६४९	१६८२५	१४०३८
करापूर्वी नफा	१६९७८	४६४५५	१५६४६	१४०३८
निव्वळ नफा	११२९७	३०२३३	१००७७	८९६९
कालावधीकरिता एकूण व्यापक उत्पन्न	१०७५५	२९६९१	१००७७	९३३५
भरणा केलेले समभाग भांडवल (दर्शनी मूल्य प्रती भाग ₹ १०)	१६९४०	१६९४०	१६९४०	८४७०
मार्च ३१, २०१८ ला संपलेल्या वर्षाकरिता लेखापरिक्षित ताळेबंदात दर्शविल्याप्रमाणे इतर इक्विटी	१९९५२५	१९९५२५	१९९५२५	१९९५२५
प्रति भाग मिळकत (ईपीएस) (₹ १० प्रत्येकी) (वार्षिक नाही)				
बेसिक आणि डायल्युटेड ईपीएस (₹)	६.६७	१७.८५	५.९५	५.२९

सूचना :

- ३१ डिसेंबर, २०१८ ला संपलेल्या तिमाही करिता वित्तीय निष्कर्षांच्या तपशिलवार स्वरुपाचे उपरोक्त सार सेबी (लिस्टिंग ऑब्लीगेशन्स अॅण्ड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजेस सोबत फाईल केले. सदर आर्थिक निष्कर्षांचे संपूर्ण स्वरुप कंपनीची वेबसाईट www.gsk-india.com येथे आणि स्टॉक एक्सचेंजेसची वेबसाईट www.nseindia.com आणि www.bseindia.com येथे उपलब्ध आहेत.
- उपरोक्त निष्कर्षांचा लेखा समितीने आढावा घेतला आणि ०४ फेब्रुवारी, २०१९ रोजी झालेल्या त्यांच्या संबंधित बैठकीत संचालक मंडळाद्वारे त्यानंतर मान्यता देण्यात आली.

मंडळाच्या आदेशाद्वारे
अण्णास्वामी वैधीश
व्यवस्थापकीय संचालक
DIN: 1444303

४ फेब्रुवारी, २०१९